Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04634240 · ClinicalTrials.gov registry record · NA

Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement

A NA study of Coronary Artery Disease and Aortic Stenosis, sponsored by University of British Columbia.

Recruiting
Registry status
NA
Development phase
4,000
Enrollment target
20
Study locations

NCT04634240: Recruiting NA study of Coronary Artery Disease and Aortic Stenosis, sponsored by University of British Columbia.

NCT04634240 is a NA study of Coronary Artery Disease and Aortic Stenosis that is actively recruiting participants, run by University of British Columbia. The registered enrollment target is 4,000 participants, above the 1,269-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (215% higher). The trial reports 20 study locations across 10 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04634240, a NA study of Coronary Artery Disease and Aortic Stenosis, is actively recruiting participants, sponsored by University of British Columbia.

RECRUITING
Registry status
NA
Development phase
4,000 participants
Enrollment target
20
Study locations

Study Summary

Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise regarding the management of concomitant CAD in patients undergoing TAVR. Some centers perform routine revascularization with percutaneous coronary intervention (PCI) (either before or after TAVR), while others follow an alternative strategy of medical management. The potential benefits and optimal timing of PCI in these patients are unknown. As TAVR expands to lower risk patients, and potentially becomes the preferred therapy for the majority of patients with severe aortic stenosis, the optimal management of concomitant coronary artery disease will be of increasing importance. The COMPLETE TAVR study will determine whether, on a background of guideline-directed medical therapy, a strategy of complete revascularization involving staged PCI using drug eluting stents to treat all suitable coronary artery lesions is superior to a strategy of medical therapy alone in reducing the composite outcome of Cardiovascular Death, new Myocardial Infarction, Ischemia-driven Revascularization or Hospitalization for Unstable Angina or Heart Failure. The study will be a randomized, multicenter, open-label trial with blinded adjudication of outcomes. Patients will be screened and consented for elective transfemoral TAVR and randomized within 96 hours of successful balloon expandable TAVR. Complete Revascularization: Staged PCI using third generation drug eluting stents to treat all suitable coronary artery lesions in vessels that are at least 2.5 mm in diameter and that are amenable to treatment with PCI and have a ≥70% visual angiographic diameter stenosis. Staged PCI can occur any time from 1 to 45 days post successful transfemoral TAVR. Vs. Medical Therapy Alone: No further revascul

Conditions Studied

Coronary Artery Disease Aortic Stenosis Coronary Stenosis

Interventions

  • PROCEDURE Percutaneous Coronary Intervention (PCI)

Study Locations (20)

California

  • Veteran Affairs Palo Alto Health Care System - Palo Alto
  • Loma Linda University - Redlands
  • Santa Barbara Cottage Hospital - Santa Barbara
  • Torrance Memorial Medical Center - Torrance

Florida

  • JFK Medical Center - Atlantis
  • Baptist Health Jacksonville - Jacksonville
  • Miami Cardiac and Vascular/Baptist Hospital - Miami

Kansas

  • University of Kansas Medical Center - Kansas City
  • Midwest Heart and Vascular - Overland Park
  • Cardiovascular Research Institute of Kansas - Wichita

Georgia

  • Piedmont - Atlanta
  • Northeast Georgia Health System - Gainesville

Indiana

  • Midwest Cardiovascular Research and Education Foundation - Elkhart
  • Parkview Research Center - Fort Wayne

Massachusetts

  • Tufts Medical - Boston
  • Massachusetts General Hospital - Boston

Alabama

  • Huntsville Heart Center - Huntsville

Arizona

  • Arizona Cardiovascular Research - Phoenix

Trial Details

FieldValue
Enrollment Target 4,000 participants
Start Date 2020-12-19
Est. Completion 2026-04-01
Phase NA
University of British Columbia

18 total trials

What NCT04634240 shows while recruiting

NCT04634240 is an interventional study that assigns participants to a tested intervention. Its 4,000 participants enrollment target places it among the larger protocols in the corpus, above the 1,269-participant average among 219 other Coronary Artery Disease trials with a reported enrollment target (215% higher).

The record links to 3 conditions, with Coronary Artery Disease appearing as the primary indexed condition, and to 1 intervention - of which Percutaneous Coronary Intervention (PCI) is the first listed.

NCT04634240 names 20 study sites across 10 states, led by California, Florida, Kansas.

Frequently Asked Questions

What is clinical trial NCT04634240 about?

NCT04634240 is a clinical study titled "Staged Complete Revascularization for Coronary Artery Disease vs Medical Management Alone in Patients With AS Undergoing Transcatheter Aortic Valve Replacement". Patients undergoing transcatheter aortic valve replacement (TAVR) often have concomitant coronary artery disease (CAD) which may adversely affect prognosis. There is uncertainty about the benefits and the optimal timing of revascularization for such patients. There is currently clinical equipoise re...

What is the current status of trial NCT04634240?

This trial is currently recruiting. It is a NA study. The enrollment target is 4,000 participants. The study started on 2020-12-19. Estimated completion is 2026-04-01.

What conditions does trial NCT04634240 study?

This clinical trial studies the following conditions: Coronary Artery Disease, Aortic Stenosis, Coronary Stenosis.

What interventions are being tested in trial NCT04634240?

The interventions under investigation include: Percutaneous Coronary Intervention (PCI) (PROCEDURE).

Who is sponsoring clinical trial NCT04634240?

This trial is sponsored by University of British Columbia, which has 18 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04634240 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Coronary Artery Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT04634240's enrollment target sits among peer trials

4,000 16th of 219 higher than 201 of 219 other Coronary Artery Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Coronary Artery Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00227253 · 4,000 participants

    Chromosome 18 Clinical Research Center

  • NCT00811148 · 4,000 participants

    Florida Center for Brain Tumor Research

  • NCT00897117 · 4,000 participants

    Collecting and Analyzing Tissue Samples From Patients Undergoing Surgery for Non-Small Cell Lung Cancer

  • NCT00899301 · 4,000 participants

    Collecting and Storing Tissue Samples From Women With or Without Breast Cancer

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

More recruiting context for NCT04634240

Source: ClinicalTrials.gov NCT04634240, the US trial registry maintained by the National Library of Medicine. NCT04634240 (large enrollment · wide site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.